Nécroses cutanées localisées aux points d’injection d’apomorphine

LeWitt, 2004, Subcutaneously administered apomorphine: pharmacokinetics and metabolism, Neurology, 62, S8, 10.1212/WNL.62.6_suppl_4.S8 Ugwoke, 2003, Intravenous versus subcutaneous injections of apomorphine in rabbits: a pharmacokinetic paradox, Boll Chim Farm, 142, 315 Colzi, 1998, Continuous subcutaneous waking day apomorphine in the long-term treatment of levodopa induced interdose dyskinesias in Parkinson's disease, J Neurol Neurosurg Psychiatry, 64, 573, 10.1136/jnnp.64.5.573 Garcia Ruiz, 2006, Nocturnal subcutaneous apomorphine infusion for severe insomnia in Parkinson's disease, Mov Disord, 21, 727, 10.1002/mds.20852 Stibe, 1988, Subcutaneous apomorphine in parkinsonian on-off oscillations, Lancet, 1, 403, 10.1016/S0140-6736(88)91193-2 Drapier, 2006, L’apomorphine en perfusion continue dans la maladie de Parkinson, Rev Neurol (Paris), 162, 1019, 10.1016/S0035-3787(06)75115-3 Dewey, 2001, A randomized, double-blind, placebo-controlled trial of subcutaneously injected apomorphine for parkinsonian off-state events, Arch Neurol, 58, 1385, 10.1001/archneur.58.9.1385 Bowron, 2004, Practical considerations in the use of apomorphine injectable, Neurology, 62, S32, 10.1212/WNL.62.6_suppl_4.S32 Pietz, 1998, Subcutaneous apomorphine in late stage Parkinson's disease: a long-term follow-up, J Neurol Neurosurg Psychiatry, 65, 709, 10.1136/jnnp.65.5.709 van Laar, 1998, The role of EDTA in provoking allergic re actions to subcutaneous infusion of apomorphine in patients with Parkinson's disease: a histologic study, Mov Disord, 13, 52, 10.1002/mds.870130113 Acland, 1998, Panniculitis in association with apomorphine infusion, Br J Dermatol, 138, 480, 10.1046/j.1365-2133.1998.02128.x Pot, 2005, Apomorphine-induced eosinophilic panniculitis and hypereosinophilia in Parkinson disease, Neurology, 64, 392, 10.1212/01.WNL.0000149757.47854.6F Todd, 2008, Apomorphine nodules in Parkinson's disease: best practice considerations, Br J Community Nurs, 13, 457, 10.12968/bjcn.2008.13.10.31182 Poltawski, 2009, Ultrsound treatment of cutaneous side-effects of infused apomophine: a randomized controlled pilot study, Mov Disord, 24, 115, 10.1002/mds.22316 Loewe, 2003, Apomorphin-Pigmentierung, Hautarzt, 54, 58 Carboni, 1997, Allergic contact dermatitis from apomorphine, Contact Dermatitis, 36, 177, 10.1111/j.1600-0536.1997.tb00417.x van Laar, 1992, Nasolabial allergic reaction to intranasal administration of apomorphine in Parkinson's disease, Ned Tijdschr Geneeskd, 136, 702 Tackenberg, 2006, Akinetic crisis caused by rectus sheath hematoma and acute anemia due to subcutaneous administration of apomorphine, Mov Disord, 21, 126, 10.1002/mds.20716 Hilary, 2004, A 10-year retrospective audit of long-term apomorphine use in Parkinson's disease, J Neurol, 251, 1370, 10.1007/s00415-004-0547-4 Amenta, 2002, The peripheral dopaminergic system: morphological analysis, functional and clinical applications, Ital J Anat Embryol, 107, 145 Manson, 2002, Apomorphine monotherapy in the treatment of refractory motor complications of Parkinson's disease: long-term follow-up study of 64 patients, Mov Disord, 17, 1235, 10.1002/mds.10281